The short answer
Copper peptides are a signalling ingredient: GHK-Cu changes which genes skin cells are reading, and the changes favour collagen synthesis and repair over inflammation and breakdown. On facial skin, published trials show measurable improvement in wrinkles and skin density over 8 to 12 weeks. The evidence base is smaller, shorter and more industry-funded than the marketing suggests, and the three figures this category quotes most often are all weaker than they sound. This page explains what each one actually measured.
Most skincare ingredients do one thing. A retinoid accelerates cell turnover. A humectant holds water. An antioxidant neutralizes free radicals. Copper peptides do something unusual: they change what your cells are instructed to build next.
If you have been researching ingredients for mature skin and keep seeing "copper peptides" without a clear explanation of what they actually do, this is that explanation. It is also, as of October 2026, a corrected one. This page previously carried a fabricated reference and five overstated claims, listed at the bottom.
What GHK-Cu copper peptide actually is
GHK (glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide first isolated from human blood plasma by Dr. Loren Pickart in 1973. His initial finding, published in Biochemical and Biophysical Research Communications, showed that when liver cells from elderly donors were exposed to blood plasma from younger donors, the older cells began synthesizing proteins more like young tissue. The active factor was a small copper-binding peptide.
When GHK binds a copper ion it forms the GHK-Cu complex, which is the form used in skincare. The copper is not decorative; it is a functional cofactor, and without it the peptide loses most of its biological activity.
Your body produces GHK-Cu naturally, and the amount falls with age: roughly 200 ng/mL in blood plasma at 20, and about 80 ng/mL at 60 (Pickart and Margolina, 2018). That decline runs alongside the visible changes we associate with aging skin, which is suggestive rather than proof of cause.
One thing worth knowing before any of the numbers below: Loren Pickart discovered this peptide and also founded a company that sells it, and he or his co-author at that company wrote much of the literature on it. That does not make the work wrong. It does mean the review papers everyone cites are not independent of the product, and we will say so each time one comes up.
Copper peptide benefits: what the research actually shows
Collagen production
There is one study that compared copper peptide head to head against other actives, and it is the most misquoted paper in this category. Abdulghani et al. (1998) compared four creams on human skin over one month with analysis of skin biopsies. What it reports are response rates, meaning how many volunteers showed any increase in procollagen synthesis:
- Copper-binding peptide cream: 7 of 10 volunteers
- Vitamin C cream: 5 of 10
- Melatonin cream: 5 of 10
- Tretinoin, a prescription retinoid: 4 of 10
This page used to say GHK-Cu "increased collagen production in 70% of subjects" against 50 and 40 percent, and that "copper peptide won convincingly." The percentages are right; the framing was not. 70 percent is the share of people who responded at all, not the size of anyone's collagen increase, and the study says nothing about how much collagen any of them gained. With ten people per arm over one month, the gap between 7 of 10 and 4 of 10 is also well inside what chance produces. It is a suggestive early result worth following up, and in twenty-eight years nobody has run the larger trial.
What is better established, from cell culture work, is that GHK-Cu stimulates production of Type I and Type III collagen and increases glycosaminoglycan synthesis, including the hyaluronic acid that holds moisture in the dermis.
Wrinkle reduction
Here the evidence is real and the headline number is routinely misread, including by us until today.
Badenhorst et al. (2016) ran a randomised, double-blind, split-face trial in 40 women aged 40 to 65 over eight weeks, with 39 completing. One wrinkle near the corner of the eye was measured on each participant with PRIMOS 3D imaging. The results:
| Wrinkle measure at 8 weeks | GHK-Cu serum | Same serum base, no GHK-Cu | Matrixyl 3000 product |
|---|---|---|---|
| Volume, change from baseline | down 24.1% | down 15.0% | down 20.0% |
| Depth, change from baseline | down 20.3% | down 15.3% | not measured in that group |
This page used to say GHK-Cu "reduced wrinkle volume by 55.8% compared to a control serum." The 55.8 percent is the relative improvement over the control side, not a 55.8 percent shrinkage of anyone's wrinkles. The actual reduction was 24.1 percent against 15.0 percent. The 31.6 percent figure against Matrixyl 3000 is correctly stated as a greater reduction than that comparator, though the matching depth comparison did not reach significance (p=0.0577).
Two disclosures the old version omitted. The trial was funded by Snowberry New Zealand, which makes the serum that was tested, and one author works at the laboratory that ran it. And the paper's own discussion credits the nano-carrier delivery system, not the peptide, with the wrinkle result. Since the test serum differed from the control by both the carrier and the GHK-Cu, the design cannot separate them.
The 12-week facial study
A GHK-Cu facial cream applied twice daily for 12 weeks by 71 women with mild to advanced photoaging improved skin density, thickness, laxity, clarity, fine lines and wrinkle depth. That is Leyden et al., an abstract presented at the American Academy of Dermatology meeting in 2002.
This page previously attributed it to "Finkley, Appa, and Bhandarkar (2005) on 67 women ages 50 to 59." Three corrections: the trial is Leyden et al. 2002, the number is 71, and no participant ages were ever published, so the 50 to 59 range was invented somewhere upstream and repeated here. Finkley, Appa and Bhandarkar (2005) is a separate book chapter. It is also worth saying that a conference abstract means the methods were never published in detail.
The old line that histology "confirmed increased dermal keratinocyte proliferation" came from that book chapter by way of Pickart and Margolina's review. It is the published wording and it is biologically muddled, because keratinocytes are epidermal, not dermal. The mechanism findings in the same review that hold up are different ones: increased integrin and p63 expression in epidermal basal cells, and increased collagen and elastin production in cultured dermal fibroblasts at 0.01 to 100 nM.
Gene modulation
This is the most interesting thing about GHK-Cu and the easiest to overstate.
Pickart and Margolina (2018) used the Broad Institute's Connectivity Map, a public library of gene expression responses to known compounds, and report that GHK changes the expression of about 31.2 percent of the human genes profiled there by 50 percent or more in either direction, raising expression in 59 percent of those and lowering it in 41 percent. The genes it raises skew toward collagen synthesis, wound healing, anti-inflammatory signalling, stem cell function and DNA repair; the ones it lowers skew toward inflammation and tissue degradation.
Three honest qualifications, none of which were on this page before. First, the paper gives the 31.2 percent without stating how many genes were profiled, so "over 4,000 genes, roughly 31% of the genome" as this page used to put it is a tighter claim than the source supports; "of the genes profiled" is the accurate phrasing. Second, this is a database analysis of gene expression, not a measurement of anything on anyone's skin, and a gene expression profile is not a clinical result. Third, both authors are affiliated with Skin Biology, a copper peptide skincare company, and the paper is a review of their own core ingredient.
The old version ended this section with "No retinoid, no vitamin C derivative, no hyaluronic acid product modulates gene expression at anything close to this scale." Nobody has run the same Connectivity Map analysis on those ingredients and published it, so that comparison was asserted rather than measured. It is gone.
How copper peptides work on mature skin
For women over 45, the mechanisms above map onto specific changes in post-menopausal skin.
Estrogen decline reduces collagen production. Brincat and colleagues (1987) measured skin collagen content and thickness in postmenopausal women and found both falling at about 1 to 2 percent per postmenopausal year, with the decline tracking years since menopause rather than chronological age. This page previously said "in the first five years after menopause, skin loses roughly 30% of its collagen." That figure has no primary study behind it. It traces to a 2005 narrative review and is repeated across the whole skincare and menopause industry; on the measured numbers the five-year loss is closer to 5 to 11 percent. The acceleration is real. It is not what this page was describing.
Sebum production drops. Without adequate natural oils the lipid barrier thins and becomes more permeable. GHK-Cu supports glycosaminoglycan production, which helps the dermis hold moisture from the inside, and a lipid-rich carrier addresses the barrier at the same time.
Chronic low-grade inflammation increases. GHK-Cu lowers expression of inflammatory genes in the Connectivity Map analysis, which is a plausible mechanism for the reduced redness and improved clarity reported in the facial studies. Mechanism and outcome, stated separately on purpose.
Wound healing slows. GHK-Cu's wound healing properties are the oldest and best-documented part of its literature, going back to Pickart's earliest work, which is why it comes up in recovery after microneedling, peels or laser treatment. That is a different evidence base from the cosmetic one and it is the stronger of the two.
This is the reasoning behind pairing methylene blue with copper peptides: methylene blue supports mitochondrial energy in fibroblasts while GHK-Cu supplies the repair signalling. The two address different bottlenecks in the same process. No trial has tested the combination, so that is a formulation rationale rather than a measured result.
How to use copper peptides in your routine
GHK-Cu is not fussy, but a few things are worth knowing.
Keep it away from acids
This page used to specify a stability window of pH 5.0 to 6.5. We removed the numbers because we could not find a source for them, and they are repeated across the category without one. What is documented is that GHK-Cu is sensitive to breakdown by carboxypeptidase enzymes (Pickart and Margolina, 2018), and the practical advice is unchanged and rests on firmer ground than the figure did: do not apply copper peptides at the same time as a low-pH vitamin C serum or an AHA or BHA exfoliant, and treat any product that combines them in one formula as unreliable. Use them at different times of day.
The carrier matters more than the concentration
The delivery system determines how much GHK-Cu reaches the dermis where fibroblasts live. That is not our marketing claim; it is the Badenhorst trial's own conclusion about its own result. Water-based serums can deliver copper peptides, but a lipid-based carrier has an advantage on mature skin because it works with a thinning barrier rather than against it.
Tallow is dominated by oleic, palmitic and stearic acid, the same three fatty acids that dominate human sebum. This page previously said grass-fed beef tallow "shares roughly 55% of its fatty acid profile with human skin lipids." We removed that figure because we could not find a published comparison behind it. Sebum also contains squalene, wax esters and sapienic acid that tallow does not, and no study shows tallow behaves like sebum, so a single similarity percentage was never a good way to describe it.
That is the reasoning behind formulations like the HealthyDerm Blue Balm using tallow as the vehicle for GHK-Cu. The carrier restores barrier lipids while delivering the peptide. Our balm has not been tested in a trial, and nothing above was measured on it.
What to avoid combining
Copper peptides and direct acids (glycolic, salicylic, L-ascorbic acid at high concentrations) should not be applied at the same time. Niacinamide, hyaluronic acid and most moisturizers layer fine with copper peptides. Retinoids and copper peptides can share a routine at different times of day; some formulators advise against combining them in one product because retinoids are formulated at a lower pH.
Copper peptide results: a realistic timeline
Week 1 to 2: If your formulation includes a lipid carrier, barrier comfort comes first. Reduced tightness, less flaking, calmer skin. That is the carrier and the anti-inflammatory signalling working in parallel.
Week 2 to 4: Improved hydration and texture as glycosaminoglycan synthesis increases. This is where most people notice the skin feels different before it looks different.
Week 4 to 8: Early firmness and softening of fine lines. Eight weeks was long enough for the Badenhorst trial to measure a difference against a control serum on 3D imaging.
Week 8 to 12: The timeframe of the Leyden 12-week facial cream study: improved laxity, clarity, firmness and wrinkle depth in 71 women with photoaging.
Beyond 12 weeks: Nobody has published a longer topical trial, so anything said about month four onward is mechanism rather than measurement. The gene data suggests continued repair signalling rather than the plateau and chronic sensitivity associated with long-term retinoid use. That is a reading of gene expression, not a result anyone has measured on a face past week 12. This page used to promise "compounding benefits" without that caveat.
The honest caveat, which was already here and is worth keeping: no topical product will reverse decades of collagen loss in a month. Anyone making that claim is selling a film-forming agent and calling it anti-aging. Copper peptides work at the pace of biology, not marketing.
One more limit, which was missing. Every figure on this page was measured on facial skin, mostly near the eye. No controlled trial has tested a topical copper peptide on the neck or jawline. If that is your concern, our turkey neck guide grades every option on the strength of its evidence for the neck specifically, and copper peptide's row says exactly this.
References
- Pickart, L., & Thaler, M. M. (1973). Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Biochemical and Biophysical Research Communications, 54(2), 562-566.
- Pickart, L., & Margolina, A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 19(7), 1987. Link. Both authors are affiliated with Skin Biology, a copper peptide skincare company.
- Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015, 648108. Link
- Badenhorst, T., Svirskis, D., Merrilees, M., Bolke, L., & Wu, Z. (2016). Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. Journal of Aging Science, 4(3), 1000166. Link. Funded by Snowberry New Zealand Ltd, the maker of the tested serum.
- Leyden, J., Stephens, T., Finkey, M., Appa, Y., & Barkovic, S. (2002). Skin Care Benefits of Copper Peptide Containing Facial Cream. American Academy of Dermatology 60th Annual Meeting, New Orleans, February 22-27, 2002, p. 68. Conference abstract, 71 women, 12 weeks.
- Finkley, M., Appa, Y., & Bhandarkar, S. (2005). Copper peptide and skin. In P. Elsner & H. Maibach (Eds.), Cosmeceuticals and Active Cosmetics: Drugs vs. Cosmetics (pp. 549-563). Marcel Dekker. Book chapter.
- Abdulghani, A. A., Sherr, S., Shirin, S., et al. (1998). Effects of topical creams containing vitamin C, a copper-binding peptide cream and melatonin compared with tretinoin on the ultrastructure of normal skin. Disease Management and Clinical Outcomes, 1(4), 136-141.
- Brincat, M., Kabalan, S., Studd, J. W., Moniz, C. F., de Trafford, J., & Montgomery, J. (1987). A study of the decrease of skin collagen content, skin thickness, and bone mass in the postmenopausal woman. Obstetrics and Gynecology, 70(6), 840-845.
Revision history
October 5, 2026. Every claim and every reference on this page was checked against its source. Seven things changed, and one of them was serious.
- A fabricated reference was removed. Entry 5 of the old reference list read: "Badenhorst, T., Svirskis, D., Wilsher, T., & O'Sullivan, J. M. (2016). Effects of GHK-Cu on MMP and TIMP Expression, Quantified by Liquid Chromatography. Peptides, 75, 88-95." No such paper exists. The real study has different co-authors, a different title, and appeared in the Journal of Aging Science, not Peptides. It is now entry 4, cited correctly. A numbered reference list that contains an invented citation is worse than no reference list, and we are naming it rather than quietly swapping it out.
- "Reduced wrinkle volume by 55.8% compared to a control serum" was corrected to the actual figures, 24.1 percent against 15.0 percent, with 55.8 percent explained as the relative improvement.
- The 12-week study was reattributed from "Finkley et al. 2005, 67 women ages 50 to 59" to Leyden et al. 2002, 71 women, ages never published.
- "In the first five years after menopause, skin loses roughly 30% of its collagen" was removed. No primary study supports it. The measured decline is 1 to 2 percent per postmenopausal year.
- "Modulates over 4,000 human genes, roughly 31% of the genome" was corrected to 31.2 percent of the genes profiled in the Connectivity Map, since the source states no denominator. The claim that no other ingredient modulates gene expression at this scale was removed as untested.
- The Abdulghani percentages are response rates, not effect sizes, and "copper peptide won convincingly" overstated a ten-per-arm one-month study. Reworded.
- The unsourced "55% of its fatty acid profile" tallow and sebum similarity figure and an unsourced pH stability range were both removed, author affiliations and trial funding were added throughout, and so was a plain statement that no controlled trial has tested a topical copper peptide on the neck or jawline.